929252-65-3Relevant articles and documents
Preparation method of aryloxy quinoline compound
-
Paragraph 0059; 0072-0076; 0092-0094; 0101-0103; 0110-0112, (2021/04/29)
The invention provides a preparation method of an aryloxy quinoline compound, and particularly provides a method for preparing an aryloxy quinoline compound with a structure shown in a formula (I) by taking 4-chloro-6-methoxy-7-quinolinol as a starting ra
PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS
-
Page/Page column 105, (2012/03/26)
The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
Pharmaceutically active compounds as Axl inhibitors
-
Paragraph 0140, (2013/03/26)
The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
Met kinase inhibitors
-
Page/Page column 17-18, (2010/11/26)
The present invention is directed to compounds that are useful for treating cancer having one of the following Formulas: